Compare · BDX vs UFPT
BDX vs UFPT
Side-by-side comparison of Becton Dickinson and Company (BDX) and UFP Technologies Inc. (UFPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and UFPT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 21.9x UFPT ($2.36B).
- UFPT has been more active in the news (12 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 7 for UFPT).
- Company
- Becton Dickinson and Company
- UFP Technologies Inc.
- Price
- $189.79-0.43%
- $303.69+0.28%
- Market cap
- $51.69B
- $2.36B
- 1M return
- -
- +22.11%
- 1Y return
- -
- +38.99%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1993
- News (4w)
- 10
- 12
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest UFPT
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the 17th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL
- Director Hudson Symeria sold $95,095 worth of shares (298 units at $319.11), decreasing direct ownership by 24% to 927 units (SEC Form 4)
- Director Hudson Symeria sold $625,141 worth of shares (1,926 units at $324.58) and exercised 1,196 shares at a strike of $206.29, decreasing direct ownership by 37% to 1,225 units (SEC Form 4)
- Director Feldmann Cynthia L sold $324,260 worth of shares (1,000 units at $324.26), decreasing direct ownership by 18% to 4,476 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Hassett Joseph John
- Executive Chairman Bailly R Jeffrey sold $4,113,221 worth of shares (13,011 units at $316.13) (SEC Form 4)
- Executive Chairman Bailly R Jeffrey sold $4,997,051 worth of shares (15,695 units at $318.38) (SEC Form 4)
- Vice President Holt Jason sold $348,700 worth of shares (1,100 units at $317.00), decreasing direct ownership by 12% to 7,878 units (SEC Form 4)
- SEC Form 10-Q filed by UFP Technologies Inc.